# US 11,110,198 B2 · Polymer particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,198 B2
- Document ID: US11110198B2
- Status: Granted
- Kind: B2
- Application number: 16/821,783
- Filed: 2020-03-17
- Published: 2020-07-09
- Granted: 2021-09-07
- Earliest claimed: 2016-09-28
- Assignees: Terumo Kabushiki Kaisha
- Applicants: Terumo Corporation
- Inventors: Gloría Hincapie; Xinping Wu; Yue Wu; Gregory M. Cruise
- Web page: https://patentgrep.com/patent/US11110198B2

## CPC

- A61L 24/0015: {Medicaments; Biocides}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 47/6927: {the form being a solid microparticle having no hollow or gas-filled cores}
- A61L 24/0042: {Materials resorbable by the body}
- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- A61L 26/0014: {obtained by reactions only involving carbon-to-carbon unsaturated bonds}
- A61L 26/0061: {Use of materials characterised by their function or physical properties}
- A61L 26/009: {Materials resorbable by the body}
- A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08F 220/56: Acrylamide; Methacrylamide
- C08F 236/20: unconjugated
- A61B 17/12109: {in a blood vessel}
- A61B 17/12113: {within an aneurysm}
- A61B 17/12181: {formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices}
- A61B 2017/00004: {(bio)absorbable, (bio)resorbable or resorptive}
- A61L 2300/204: with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L 2300/224: containing metals, e.g. porphyrins, vitamin B12
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

## Claims

### Claim 1

An embolic composition including:
polymer particles comprising at least one monomer including at least one functional group, at least one crosslinker having a structure
at least one pharmaceutical agent.

### Claim 2 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agent is a positively charged pharmaceutical agent.

### Claim 3 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agent is a negatively charged pharmaceutical agent.

### Claim 4 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agent is irinotecan, doxorubicin, epirubicin, idarubicin, or a combination thereof.

### Claim 5 (depends on 1)

The embolic composition of claim 1, wherein the polymer particles have a diameter between about 40 μm and about 1,200 μm.

### Claim 6 (depends on 1)

The embolic composition of claim 1, wherein the polymer particles have a diameter between about 75 μm and about 1,200 μm.

### Claim 7 (depends on 1)

The embolic composition of claim 1, wherein the at least one functional group is acrylate, acrylamide, methacrylate, or methacrylamide.

### Claim 8 (depends on 1)

The embolic composition of claim 1, wherein the at least one monomer includes an ionizable functional group.

### Claim 9 (depends on 8)

The embolic composition of claim 8, wherein the ionizable functional group is basic.

### Claim 10 (depends on 8)

The embolic composition of claim 8, wherein the ionizable functional group is acidic.

### Claim 11 (depends on 1)

The embolic composition of claim 1, wherein the polymer particles include a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.

### Claim 12 (depends on 1)

The embolic composition of claim 1, wherein the polymer particles are biodegradable.

### Claim 13 (depends on 1)

The embolic composition of claim 1, wherein the polymer particles are substantially degraded within about 1 months of implantation.

### Claim 14 (depends on 1)

The embolic composition of claim 1, wherein the at least one monomer is dimethylacrylamide.

### Claim 15 (depends on 1)

The embolic composition of claim 1, wherein the at least one monomer is acrylamide.

### Claim 16 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agents is at least 90% eluted over the first day of implantation.

### Claim 17 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agents is at least 60% eluted over the first day of implantation.

### Claim 18 (depends on 1)

The embolic composition of claim 1, wherein the at least one pharmaceutical agent is at a highest concentration in situ less than about 1 hour after implantation.

### Claim 19 (depends on 1)

A method of treatment, the method comprising:
delivering the embolic solution of claim 1 through a delivery device to a treatment site.

### Claim 20 (depends on 19)

The method of claim 19, wherein the delivering is through a catheter, a microcatheter, or a needle.